thyroxine has been researched along with Adenocarcinoma Of Kidney in 17 studies
Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.
thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Subclinical hypothyroidism was characterized by serum TSH above the upper limit of normal and both total triiodothyronine (T3) and thyroxine (T4) within normal limits." | 7.77 | Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. ( Bierer, S; Herrmann, E; Hertle, L; Hoffmeister, I; Köpke, T; Papavassilis, P; Riesenbeck, LM; Thielen, B, 2011) |
| " Hypothyroidism was considered present if thyroid-stimulating hormone (TSH) exceeded the upper normal limit (UNL) with normal triiodothyronine (T3) and thyroxine (T4)." | 3.78 | Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma? ( Hanovich, E; Hercbergs, AH; Kovel, S; Sella, A, 2012) |
| " Subclinical hypothyroidism was characterized by serum TSH above the upper limit of normal and both total triiodothyronine (T3) and thyroxine (T4) within normal limits." | 3.77 | Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. ( Bierer, S; Herrmann, E; Hertle, L; Hoffmeister, I; Köpke, T; Papavassilis, P; Riesenbeck, LM; Thielen, B, 2011) |
| " There were no changes in T4 concentrations during chronic administration of rhIL-6." | 2.67 | Effects of acute and chronic interleukin-6 administration on thyroid hormone metabolism in humans. ( Bakker, PJ; Endert, E; Romijn, JA; Sauerwein, HP; Stouthard, JM; van der Poll, T; Veenhof, CH, 1994) |
| "Bexarotene has been FDA-approved for the treatment of CTCL, but previous studies have been conducted on CD4+ CTL and there have been no reports about its use in CD8+ CTCL." | 2.44 | CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature. ( Abbott, L; Farah, R; Gopaluni, S; Hutchison, R; Perzova, R; Poiesz, BJ; Shrimpton, A, 2008) |
| "To evaluate the incidence, diagnosis and treatment of immune-related adverse events (e-irAE) of checkpoint inhibition (ICI) in metastatic urothelial carcinoma (mUC) and metastatic renal cell carcinoma (mRCC)." | 1.91 | Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors. ( Burger, M; Büttner, R; Oppolzer, IA; Riester, J; Schnabel, MJ, 2023) |
| "Renal cell carcinoma is the most lethal of the common urologic malignancies, with no available effective therapeutics." | 1.35 | Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts. ( Bharali, DJ; Davis, FB; Davis, PJ; Dyskin, E; Hercbergs, A; Lansing, L; Mousa, SA; Mousa, SS; Yalcin, M, 2009) |
| "Clinical presentation included bitemporal hemianopia (3 patients), lethargy (3), headaches (2) and diabetes insipidus (DI) (2)." | 1.34 | Symptomatic pituitary metastases from renal cell carcinoma. ( Gopan, T; Hamrahian, AH; Prayson, RA; Suh, JH; Toms, SA; Weil, RJ, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Oppolzer, IA | 1 |
| Riester, J | 1 |
| Büttner, R | 1 |
| Burger, M | 1 |
| Schnabel, MJ | 1 |
| Pani, F | 1 |
| Atzori, F | 1 |
| Baghino, G | 1 |
| Boi, F | 1 |
| Tanca, L | 1 |
| Ionta, MT | 1 |
| Mariotti, S | 1 |
| Gopaluni, S | 1 |
| Perzova, R | 1 |
| Abbott, L | 1 |
| Farah, R | 1 |
| Shrimpton, A | 1 |
| Hutchison, R | 1 |
| Poiesz, BJ | 1 |
| Alexandrescu, DT | 1 |
| Popoveniuc, G | 1 |
| Farzanmehr, H | 1 |
| Dasanu, CA | 1 |
| Dawson, N | 1 |
| Wartofsky, L | 1 |
| Yalcin, M | 1 |
| Bharali, DJ | 1 |
| Lansing, L | 1 |
| Dyskin, E | 1 |
| Mousa, SS | 1 |
| Hercbergs, A | 1 |
| Davis, FB | 1 |
| Davis, PJ | 1 |
| Mousa, SA | 1 |
| Riesenbeck, LM | 1 |
| Bierer, S | 1 |
| Hoffmeister, I | 1 |
| Köpke, T | 1 |
| Papavassilis, P | 1 |
| Hertle, L | 1 |
| Thielen, B | 1 |
| Herrmann, E | 1 |
| Pérez López, G | 1 |
| Carrasco De La Fuente, M | 1 |
| Menacho Román, M | 1 |
| González Albarrán, O | 1 |
| Cano Megías, M | 1 |
| Block, MS | 1 |
| Kohli, M | 1 |
| Kappers, MH | 1 |
| van Esch, JH | 1 |
| Smedts, FM | 1 |
| de Krijger, RR | 1 |
| Eechoute, K | 1 |
| Mathijssen, RH | 1 |
| Sleijfer, S | 1 |
| Leijten, F | 1 |
| Danser, AH | 1 |
| van den Meiracker, AH | 1 |
| Visser, TJ | 1 |
| Sella, A | 2 |
| Hercbergs, AH | 1 |
| Hanovich, E | 1 |
| Kovel, S | 1 |
| Del Fabbro, E | 1 |
| Dev, R | 1 |
| Cabanillas, ME | 1 |
| Busaidy, NL | 1 |
| Rodriguez, EC | 1 |
| Bruera, E | 1 |
| Sartore-Bianchi, A | 1 |
| Soriani, A | 1 |
| Mattioni, R | 1 |
| Vaglio, A | 1 |
| Buzio, C | 1 |
| Porta, C | 1 |
| Gopan, T | 1 |
| Toms, SA | 1 |
| Prayson, RA | 1 |
| Suh, JH | 1 |
| Hamrahian, AH | 1 |
| Weil, RJ | 1 |
| Grossmann, M | 1 |
| Premaratne, E | 1 |
| Desai, J | 1 |
| Davis, ID | 1 |
| Stouthard, JM | 1 |
| van der Poll, T | 1 |
| Endert, E | 1 |
| Bakker, PJ | 1 |
| Veenhof, CH | 1 |
| Sauerwein, HP | 1 |
| Romijn, JA | 1 |
| Späth-Schwalbe, E | 1 |
| Schrezenmeier, H | 1 |
| Bornstein, S | 1 |
| Burger, K | 1 |
| Porzsolt, F | 1 |
| Born, J | 1 |
| Vassilopoulou-Sellin, R | 1 |
| Dexeus, FH | 1 |
| Theriault, RL | 1 |
| Pololoff, DA | 1 |
1 review available for thyroxine and Adenocarcinoma Of Kidney
| Article | Year |
|---|---|
CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.
Topics: Antineoplastic Agents; Azetidines; Bexarotene; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Co | 2008 |
2 trials available for thyroxine and Adenocarcinoma Of Kidney
| Article | Year |
|---|---|
Effects of acute and chronic interleukin-6 administration on thyroid hormone metabolism in humans.
Topics: Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Female; Humans; Interleukin-6; Kidney Neopl | 1994 |
Endocrine effects of recombinant interleukin 6 in man.
Topics: Carcinoma, Renal Cell; Hormones; Humans; Interleukin-6; Kidney Neoplasms; Luteinizing Hormone; Male; | 1996 |
14 other studies available for thyroxine and Adenocarcinoma Of Kidney
| Article | Year |
|---|---|
Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors.
Topics: Antineoplastic Agents, Immunological; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Humans; H | 2023 |
Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved?
Topics: Adult; Aged; Antineoplastic Agents; Autoantibodies; Autoimmunity; Carcinoma, Renal Cell; Female; Hum | 2015 |
Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies.
Topics: Antibodies, Anti-Idiotypic; Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Renal Cell; Dose- | 2008 |
Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts.
Topics: Animals; Carcinoma, Renal Cell; Cell Growth Processes; Cell Line, Tumor; Chick Embryo; Chorioallanto | 2009 |
Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Fem | 2011 |
[Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].
Topics: Adult; Benzamides; Benzenesulfonates; Carcinoma, Renal Cell; Choristoma; Female; Gastrointestinal St | 2011 |
Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Hypothyroidism; Lung Neopla | 2011 |
Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression.
Topics: Aged; Animals; Antineoplastic Agents; Body Weight; Capillaries; Carcinoma, Renal Cell; Female; Gastr | 2011 |
Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans | 2012 |
Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer.
Topics: Adult; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Renal Cell; Drug Resistance; Fatal Outcom | 2012 |
Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; | 2004 |
Symptomatic pituitary metastases from renal cell carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Combined Modality Therapy; Deamino Arginine Vasopressin; Diabetes Insip | 2007 |
Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male | 2008 |
Acute thyroid dysfunction (thyroiditis) after therapy with interleukin-2.
Topics: Adult; Carcinoma, Renal Cell; Female; Humans; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Mal | 1992 |